Science & Technology Review >

2019 , Vol. 37 >Issue 22: 113 - 125

DOI: https://doi.org/10.3981/j.issn.1000-7857.2019.22.013

Review

Research trend of worldwide lung cancer during recent 40 years based on bibliometric analysis

  • XU Zhiyong ,
  • DONG Zhiqiang
Expand
  • 1. College of Biomedicine and Health, Huazhong Agricultural University, Wuhan 430070, China;
    2. College of Life Science and Technology, Huazhong Agricultural University, Wuhan 430070, China

Received date: 2019-05-16

  Revised date: 2019-08-04

  Online published: 2019-11-30

Fold

Abstract

The present study analyzes the worldwide research status and the development trend of the lung cancer based on papers published in SCI-indexed journals, with bibliometric analysis of the data from the SCI-E database of the WoS during 1979-2018 to assess the research situations of the lung cancer based on the number of articles, the year of publication, the countries, the institutes, the sources of journals, the discipline fields and the highly cited papers in ESI. There are 178694 published papers in total. It is indicated that the number of yearly published articles shows an overall upward trend all over the world. Among all countries, the top 10 countries are the USA, China, Japan, Italy, Germany, England, France, Canada, South Korea, and Netherlands. Harvard University of the USA has obvious advantages on the research of the lung cancer. Worldwide research activities in the field of the lung cancer show the characteristics of an interdisciplinary development. The rank of the journals, institutes and highly cited papers are overwhelmingly dominated by those from the USA. Shanghai Jiaotong University is the only institute in China in the top 10 publishing institutes. In recent years, the number of lung cancer articles from China published in SCI-indexed journals has been increased dramatically and has ranked the 2nd in the world, but the quality of articles is not as good as the quantity. The research of the lung cancer in China should be closely integrated with the clinical application.

Key words： lung cancer research; bibliometric; lung cancer research trend

Cite this article

XU Zhiyong , DONG Zhiqiang . Research trend of worldwide lung cancer during recent 40 years based on bibliometric analysis[J]. Science & Technology Review, 2019 , 37(22) : 113 -125 . DOI: 10.3981/j.issn.1000-7857.2019.22.013

References

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA:A Cancer Journal for Clinicians, 2018, 68(6):394-424.
[2] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2019[J]. CA:A Cancer Journal for Clinicians, 2019, 69(1):7-34.
[3] 陈万青, 孙可欣, 郑荣寿, 等. 2014年中国分地区恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2018, 27(1):1-14. Chen Wanqing, Sun Kexin, Zheng Rongshou, et al. Report of cancer incidence and mortality in different areas of China, 2014[J]. China Cancer, 2018, 27(1):1-14
[4] 吕关平, 陈磊, 沈珍瑶. 基于文献计量学的长江三峡水库研究进展[J]. 科技导报, 2015, 33(9):108-119. Lü Guanping, Chen Lei, Shen Zhenyao. Progress on three gorges reservoir research:From a bibliometrics perspective[J]. Science & Technology Review, 2015, 33(9):108-119.
[5] Ren Y G, Wang Q J, Tian L, et al. Bibliometric analysis on lung cancer in China during the period of 2001-2010[J]. Thoracic Cancer, 2012, 3(4):363-366.
[6] Ho Y S, Satoh H, Lin S Y. Japanese lung cancer research trends and performance in Science Citation Index[J]. Internal Medicine, 2010, 49(20):2219-2228.
[7] Ho Y S, Nakazawa K, Sato S, et al. Cisplatin for small cell lung cancer:Associated publications in Science Citation Index Expanded[J]. Oncology Letters, 2013, 5(2):684-688.
[8] 丁宁. 我国肺癌相关研究现状与热点的文献计量分析[J]. 中华医学图书情报杂志, 2014, 23(4):67-72. Ding Ning. Status quo and hot spots of lung cancer-related studies in China:A bibliometric analysis[J]. Chinese Journal of Medical Library and Information Science, 2014, 23(4):67-72.
[9] He X R, Han S Y, Li P P. Recent highlights of Chinese medicine for advanced lung cancer[J]. Chinese Journal of Integrative Medicine, 2017, 23(5):323-330.
[10] 李艳, 陆晴, 李雅梅. 肺癌症状群研究英文文献计量分析[J]. 护理学杂志, 2018, 33(9):92-97. Li Yan, Lu Qing, Li Yamei. Bibliometric analysis of English written articles regarding symptom clusters in lung cancer patients[J]. Journal of Nursing Science, 2018, 33(9):92-97.
[11] 刘彬, 陈柳, 袁佩佩. 国家自然科学基金资助的2009-2013年SCI收录文献计量分析[J]. 中国科学基金, 2014, 28(3):214-218. Liu Bin, Chen Liu, Yuan Peipei. Bibliometric analysis on SCI covered papers funded by NSFC from 2009 to 2013[J]. Bulletin of National Natural Science Foundation of China, 2014, 28(3):214-218.
[12] 刘彬, 邓秀新. 基于文献计量的园艺学基础研究发展状况分析[J]. 中国农业科学, 2015, 48(17):3504-3514. Liu Bin, Deng Xiuxin. Basic research development status of horticulture based on bibliometric analysis[J]. Scientia Agricultura Sinica, 2015, 48(17):3504-3514.
[13] 叶鹰. H指数和类H指数的机理分析与实证研究导引[J]. 大学图书馆学报, 2007, 25(5):2-5. Ye Ying. An introduction to mechanic analysis and positive researches of H-index and H-like indexes[J]. Journal of Academic Libraries, 2007, 25(5):2-5.
[14] Van-Haselen R. The h-index:A new way of assessing the scientific impact of individual CAM authors[J]. Complementary Therapies in Medicine, 2007, 15(4):225-227.
[15] 孙颉. 基于文献计量的国内外柿研究现状分析[J]. 果树学报, 2017, 34(6):706-714. Sun Jie. Current situation of persimmon science and technology in the world based on bibliometrics analysis[J]. Journal of Fruit Science, 2017, 34(6):706-714.
[16] 李小涛. ESI高被引论文视角下图情学科的发展与创新[J]. 中华医学图书情报杂志, 2016, 25(10):52-58. Li Xiaotao. Development and innovation in library and information science in view of ESI-based highly cited papers[J]. Chinese Journal of Medical Library and Information Science, 2016, 25(10):52-58.
[17] 陈楠楠, 李娟, 魏青山. ESI高被引论文收录和引证分析探索[J]. 情报探索, 2018, 12:39-43. Chen Nannan, Li Juan, Wei Qingshan. Exploration on the collection and citation analysis of ESI highly citied papers[J]. Information Research, 2018, 12:39-43.
[18] Jemal A, Bray F, Center M M, et al. Global cancer statistics[J]. CA:A Cancer Journal for Clinicians, 2011, 61(2):69-90.
[19] Torre L A, Bray F, Siegel R L, et al. Global cancer statistics, 2012[J]. CA:A Cancer Journal for Clinicians, 2015, 65(2):87-108.
[20] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide:Sources, methods and major patterns in Globocan 2012[J]. International Journal of Cancer, 2015, 136(5):E359-E386.
[21] Ferlay J, Shin H R, Bray F, et al. Estimates of worldwide burden of cancer in 2008:Globocan 2008[J]. International Journal of Cancer, 2010, 127(12):2893-2917.
[22] Siegel R, Naishadham D, Jemal A, et al. Cancer statistics, 2012[J]. CA:A Cancer Journal for Clinicians, 2012, 62(1):10-29.
[23] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2016[J]. CA:A Cancer Journal for Clinicians, 2016, 66(1):7-30.
[24] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA:A Cancer Journal for Clinicians, 2013, 63(1):11-30.
[25] Siegel R, Ma J M, Zou Z H, et al. Cancer statistics, 2014[J]. CA:A Cancer Journal for Clinicians, 2014, 64(1):9-29.
[26] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2015[J]. CA:A Cancer Journal for Clinicians, 2015, 65(1):5-29.
[27] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2017[J]. CA:A Cancer Journal for Clinicians, 2017, 67(1):7-30.
[28] Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:A systematic analysis for the global burden of disease study 2010[J]. Lancet, 2012, 380(9859):2095-2128.
[29] Topalian S L, Hodi F S, Brahmer J R, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. New England Journal of Medicine, 2012, 366(26):2443-2454.
[30] Lim S S, Vos T, Flaxman A D, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010:A systematic analysis for the global burden of disease study 2010[J]. Lancet, 2012, 380(9859):2224-2260.
[31] Chen W Q, Zheng R S, Baade P D, et al. Cancer statistics in China, 2015[J]. CA:A Cancer Journal for Clinicians, 2016, 66(2):115-132.
[32] Mok T S, Wu Y L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. New England Journal of Medicine, 2009, 361(10):947-957.
[33] Gerlinger M, Rowan A J, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing[J]. New England Journal of Medicine, 2012, 366(10):883-892.
[34] Brahmer J R, Tykodi S S, Chow L Q M, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J]. New England Journal of Medicine, 2012, 366(26):2455-2465.
[35] Aberle D R, Adams A M, Berg C D, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening[J]. New England Journal of Medicine, 2011, 365(5):395-409.
[36] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2018[J]. CA:A Cancer Journal for Clinicians, 2018, 68(1):7-30.
[37] Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J]. New England Journal of Medicine, 2010, 362(25):2380-2388.
Options
Outlines

/

〈 〉

Contact

  • Add：No. 86 Xueyuan South Road, Haidian District, Beijing　 Postal Code：100081
  • Tel: +86-10-62138113　Fax: +86-10-62138113
  • E-mail：kjdbbjb@cast.org.cn

    • Visited

      Total visitors:
      Visitors of today:
      Now online:
    Copyright © Science & Technology Review, All Rights Reserved.